Florian Ewald1, Falk Wuesthoff2, Robert Koehnke2, Reinhard E Friedrich2, Martin Gosau2, Ralf Smeets3, Holger Rohde4, Alexandre T Assaf5. 1. Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg Eppendorf, University of Hamburg, Hamburg, Germany. 2. Department of Oral and Maxillofacial Surgery, University Medical Centre Hamburg Eppendorf, University of Hamburg, 20246, Hamburg, Germany. 3. Department of Oral and Maxillofacial Surgery, Division of Regenerative Orofacial Medicine, University Medical Centre Hamburg Eppendorf, University of Hamburg, Hamburg, Germany. 4. Department of Medical Microbiology, Virology and Hygiene, University Medical Centre Hamburg Eppendorf, University of Hamburg, Hamburg, Germany. 5. Department of Oral and Maxillofacial Surgery, University Medical Centre Hamburg Eppendorf, University of Hamburg, 20246, Hamburg, Germany. a.assaf@uke.de.
Abstract
OBJECTIVES: The aim of our study was to describe microbial flora associated with MRONJ and characterize the susceptibility of pathogens to help guide an effective empiric antibiotic treatment in these patients. MATERIALS AND METHODS: A retrospective, single-center analysis was performed, using 116 bone samples from 98 patients. The bone samples were homogenized and subjected to routine culture methods. Growing bacteria were differentiated to the species level using whole-cell mass spectrometry and subjected to susceptibility testing. RESULTS: A highly diverse microbial flora was detected in necrotic bone, with a simultaneous presence of two or more bacterial species in 79% of all patients. In at least 65% of samples, gram-negative isolates were detected. Therefore, bacterial species resistant against β-lactamase inhibitors were present in at least 70% of all patients. CONCLUSIONS: The empiric choice of antibiotics in MRONJ patients should consider the high rate of gram-negative bacteria and resistance against β-lactam antibiotics. CLINICAL RELEVANCE: According to recent guidelines and recommendations, systemic antibiotic treatment is a key component in the treatment of all stage 2 and 3 MRONJ patients. We recommend using fluoroquinolones for empiric treatment and emphasize the use of bacterial cultivation and susceptibility testing to enable an effective antibiotic treatment.
OBJECTIVES: The aim of our study was to describe microbial flora associated with MRONJ and characterize the susceptibility of pathogens to help guide an effective empiric antibiotic treatment in these patients. MATERIALS AND METHODS: A retrospective, single-center analysis was performed, using 116 bone samples from 98 patients. The bone samples were homogenized and subjected to routine culture methods. Growing bacteria were differentiated to the species level using whole-cell mass spectrometry and subjected to susceptibility testing. RESULTS: A highly diverse microbial flora was detected in necrotic bone, with a simultaneous presence of two or more bacterial species in 79% of all patients. In at least 65% of samples, gram-negative isolates were detected. Therefore, bacterial species resistant against β-lactamase inhibitors were present in at least 70% of all patients. CONCLUSIONS: The empiric choice of antibiotics in MRONJ patients should consider the high rate of gram-negative bacteria and resistance against β-lactam antibiotics. CLINICAL RELEVANCE: According to recent guidelines and recommendations, systemic antibiotic treatment is a key component in the treatment of all stage 2 and 3 MRONJ patients. We recommend using fluoroquinolones for empiric treatment and emphasize the use of bacterial cultivation and susceptibility testing to enable an effective antibiotic treatment.
Entities:
Keywords:
ARONJ; Antibiotic resistance; Antiresorptive drug-induced osteonecrosis of the jaw; Bacterial colonization; MRONJ; Medication-related osteonecrosis of the jaw; Oral microbiota
Authors: Alexandre T Assaf; Ralf Smeets; Björn Riecke; Eva Weise; Alexander Gröbe; Marco Blessmann; Tim Steiner; Johannes Wikner; Reinhard E Friedrich; Max Heiland; Frank Hoelzle; Frank Gerhards Journal: Anticancer Res Date: 2013-09 Impact factor: 2.480
Authors: Christine Jacobsen; Philipp Metzler; Joachim Anton Obwegeser; Wolfgang Zemann; Klaus Wilhelm Graetz Journal: Swiss Med Wkly Date: 2012-06-26 Impact factor: 2.193
Authors: B Galis; J Zajko; D Hirjak; L Vanko; I Kupcova; J Jurkemik; P Gengelova; K Mikuskova; K Halmova; M Riznic; L Czako Journal: Bratisl Lek Listy Date: 2017 Impact factor: 1.278
Authors: Anna Winter; Stefan M Schulz; Marc Schmitter; Roman C Brands; Anton Straub; Alexander Kübler; Anna Borgmann; Stefan Hartmann Journal: Int J Environ Res Public Health Date: 2022-09-16 Impact factor: 4.614